Holmes Greg
Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, One Gustave L. Levy Place, 1428 Madison Avenue, New York, NY 10029, USA.
Childs Nerv Syst. 2012 Sep;28(9):1505-10. doi: 10.1007/s00381-012-1872-z. Epub 2012 Aug 8.
Apert syndrome is one of the more clinically distinct craniosynostosis syndromes in man. It is caused by gain-of-function mutations in FGFR2, over 98% of which are the two amino acid substitution mutations S252W and P253R. FGFR2 is widely expressed throughout development, so that many tissues are adversely affected in Apert syndrome, particularly the calvarial bones, which begin to fuse during embryonic development, and the brain.
Mouse models of both of these two causative mutations and a third rare splice mutation have been created and display many of the phenotypes typical of Apert syndrome. The molecular and cellular mechanisms underlying Apert phenotypes have begun to be elucidated, and proof-of-principle treatment of these phenotypes by chemical inhibitor and gene-based therapies has been demonstrated.
阿佩尔综合征是人类临床上较为独特的颅缝早闭综合征之一。它由成纤维细胞生长因子受体2(FGFR2)的功能获得性突变引起,其中超过98%是两个氨基酸替代突变S252W和P253R。FGFR2在整个发育过程中广泛表达,因此阿佩尔综合征会对许多组织产生不利影响,尤其是在胚胎发育期间开始融合的颅骨和大脑。
已经创建了这两种致病突变以及第三种罕见剪接突变的小鼠模型,这些模型表现出许多阿佩尔综合征典型的表型。阿佩尔综合征表型背后的分子和细胞机制已开始得到阐明,并且已经证明了通过化学抑制剂和基于基因的疗法对这些表型进行原理验证治疗的可行性。